These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 6586112

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Phase II trial of vindesine in patients with acute leukemia.
    Sklaroff RB, Arlin Z, Young CW.
    Cancer Treat Rep; 1979; 63(11-12):2063-5. PubMed ID: 294307
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
    Lemez P, Vítek A, Jelínek J, Lukásová M, Palecek A, Sajdová J, Jedlicková A, Vorlová Z.
    Vnitr Lek; 1995 Jan; 41(1):34-9. PubMed ID: 7716891
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Administration of vindesine sulfate for the treatment of malignant hematological tumors].
    Ueda T, Masaoka T, Shibata H, Kubota Y, Saigo K, Kusakabe H, Takubo T, Nakamura H, Yoshitake J, Ishigami S.
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):306-15. PubMed ID: 6764103
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
    Saito K.
    Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
    [Abstract] [Full Text] [Related]

  • 36. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
    Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ.
    J Clin Oncol; 1986 Jul; 4(7):1079-88. PubMed ID: 3459811
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
    Lemez P, Gáliková J, Haas T.
    Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
    [Abstract] [Full Text] [Related]

  • 39. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Jun; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.